Cary Street Partners Financial LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 7,237 shares of the medical research company's stock, valued at approximately $1,422,000.
A number of other hedge funds have also added to or reduced their stakes in the stock. Howard Capital Management Inc. grew its holdings in IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after purchasing an additional 54 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in IQVIA by 1.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock valued at $1,068,000 after purchasing an additional 56 shares during the last quarter. Cypress Wealth Services LLC increased its stake in shares of IQVIA by 4.8% in the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock worth $244,000 after purchasing an additional 57 shares in the last quarter. Harbor Investment Advisory LLC raised its position in shares of IQVIA by 4.7% in the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock valued at $253,000 after purchasing an additional 58 shares during the period. Finally, Magnolia Capital Advisors LLC lifted its stake in shares of IQVIA by 2.9% during the 4th quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company's stock valued at $516,000 after buying an additional 74 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on IQV shares. Royal Bank of Canada reiterated an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Hsbc Global Res lowered shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Truist Financial decreased their target price on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Finally, Robert W. Baird decreased their price target on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a report on Wednesday. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $231.71.
Read Our Latest Stock Analysis on IQV
IQVIA Stock Down 2.9 %
Shares of IQV traded down $4.39 during mid-day trading on Friday, reaching $148.90. The company had a trading volume of 1,677,229 shares, compared to its average volume of 1,469,448. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a 50-day moving average price of $163.91 and a 200 day moving average price of $188.25. IQVIA Holdings Inc. has a 52 week low of $135.97 and a 52 week high of $252.88. The company has a market capitalization of $25.76 billion, a price-to-earnings ratio of 19.85, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34.
IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm's quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the firm earned $2.54 earnings per share. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
